Company profile: BioSenic
1.1 - Company Overview
Company description
- Provider of therapies addressing innate immunity, inflammation, and organ/function repair, including arsenic trioxide-based treatments for autoimmune diseases and chronic graft versus host disease (ArsciCor, an oral formulation with rapid gastrointestinal solubilization and optimal bioavailability), cell therapy products for major bone defects and maxillofacial applications, and a Phase III trial of oral arsenic trioxide.
Products and services
- ArsciCor: Oral arsenic trioxide formulation for treating chronic graft versus host disease, offering rapid gastrointestinal solubilization and optimal bioavailability
- Cell therapy products: Regenerative cell-based products developed for treatments of major bone defects and maxillofacial applications
- Phase III clinical trial for OATO: Phase III clinical study evaluating the efficacy and safety of oral arsenic trioxide as a first-line treatment for chronic graft versus host disease
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to BioSenic
Aera Therapeutics
HQ: United States
Website
- Description: Provider of a proprietary protein nanoparticle (PNP) delivery platform based on human proteins to deliver genetic medicines across modalities and therapeutic areas, and a therapeutic enzyme platform with novel, compact, programmable gene-editing enzymes to overcome packaging and delivery challenges in gene therapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aera Therapeutics company profile →
Allenex
HQ: Sweden
Website
- Description: Provider of products for blood stem cell and organ transplantation, including genomic HLA typing kits used prior to hematopoietic stem cell/bone marrow and organ transplants to match donors; develops, manufactures, markets, and sells worldwide.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Allenex company profile →
Noveome Biotherapeutics
HQ: United States
Website
- Description: Provider of regenerative repair therapies for inflamed or damaged tissues via ST266, a multi-targeted secretome of biologically active proteins for neuroprotection, inflammation modulation, cell recovery, and healing in ophthalmology, neurology, and dermatology; explored in PEDs, optic neuritis, glaucoma (Phase I), NEC, and COVID-19/sepsis cytokine storm.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Noveome Biotherapeutics company profile →
OMass Therapeutics
HQ: United Kingdom
Website
- Description: Provider of drug discovery leveraging novel mass spectrometry, offering the OdyssION platform that uses native mass spectrometry and custom chemistry to study target interactions in native ecosystems, and a small molecule pipeline targeting solute carriers, inflammasome complexes, and GPCRs for orphan and immunological diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OMass Therapeutics company profile →
Step Pharma
HQ: France
Website
- Description: Provider of CTPS1 inhibition therapies, developing STP938, an orally bioavailable CTPS1 inhibitor in clinical development for treating blood cancers and potentially solid tumors. The approach targets the CTPS1 enzyme to inhibit a key step in nucleotide synthesis to treat various cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Step Pharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for BioSenic
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to BioSenic
2.2 - Growth funds investing in similar companies to BioSenic
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for BioSenic
4.2 - Public trading comparable groups for BioSenic
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →